Search
Leucine-rich repeat serine/threonine-protein kinase 2
go.drugbank.com/bio_entities/BE0009457TargetHumansSerine/threonine-protein kinase which phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking (PubMed:17114044, PubMed:20949042, PubMed:2185...
Polypeptides: Leucine-rich repeat serine/threonine-protein kinase 216S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA
go.drugbank.com/bio_entities/BE0009727TargetMycobacterium tuberculosis (strain ATCC 25618 / H37Rv)Catalyzes the 2'-O-methylation at nucleotides C1409 in 16S rRNA and C1920 in 23S rRNA (PubMed:16857584, PubMed:20854656). Is likely involved in ribosomal biogenesis (PubMed:21443791).
Polypeptides: 16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyASynonyms: 16S rRNA (cytidine1409-2'-O)-methyltransferase, 23S rRNA (cytidine1920-2'-O)-methyltransferaseBivalirudin
go.drugbank.com/drugs/DB00006ApprovedInvestigationalBivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin.
Products: OBIVADIN 250 MG IV ENJEKSIYON/INFÜZYON IÇIN LIYOFILIZE TOZ, 1 ADET, BIVACARD 250 MG IV ENJEKSIYON VE INFÜZYON IÇIN LIYOFILIZE TOZ IÇEREN FLAKON, 1 ADETOpium
go.drugbank.com/drugs/DB11130ApprovedIllicitIt has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. … [L1762] Opium has gradually been superseded by a variety of synthetic opioids and general anesthetics.
Mixtures: Donnagel-PG Liq, Donnagel-PG CapCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesRabeprazole
go.drugbank.com/drugs/DB01129ApprovedInvestigationalRabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. … It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form.
Mixtures: RABEDIC 20/75 MG MR KAPSÜL, 20 ADET, RABEDIC MR 20/100 MG KAPSÜL, 20 ADETCategories: 2-Pyridinylmethylsulfinylbenzimidazoles, Heterocyclic Compounds, 2-RingDrospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigationalDrospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. … Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events.
Mixtures: Angeliq 1 mg/2 mg Filmtabletten, ANGELIQ 1 MG/2 MG FILM KAPLI TABLET, 28 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBupropion
go.drugbank.com/drugs/DB01156ApprovedInvestigationalBupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective … [L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo
Mixtures: Appbutamone-DCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesEnfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalThe first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells. … Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesProducts: FUZEON POLVO SOLUCION INYECTABLE 90 MG/MIRuxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalRuxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … It is a potent and selective inhibitor of JAK1 and JAK2,[A229698] which are tyrosine kinases involved in cytokine signalling and hematopoiesis.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: JAKAVI 20 MG (TABLETS), JAKAVI 20 MG TABLET, 168 TABLETFinerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigational[A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449] … Finerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 SubstratesProducts: KERENDİA 20 MG FİLM KAPLI TABLET, 28 ADET, KERENDİA 20 MG FİLM KAPLI TABLET, 98 ADET